Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lorena Garcia

Nurse Practitioner, Psychiatric/Mental Health Las Cruces, NM Nurse Practitioner

NPI 1457694606 CMS profile 10641888

1990 E Lohman Ave Ste A, Las Cruces, NM 88001

Open in the dashboard

General payments

$5,926

340 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lorena Garcia of Las Cruces, NM is reported in the CMS Open Payments database as having received $5,926 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,315 84
2024 General $1,414 72
2023 General $1,134 47
2022 General $887 52
2021 General $1,176 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lorena Garcia
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Lorena Garcia were reported at $1,315. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Lorena Garcia Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,176 $166 $54–$482 $132
2022 $887 $195 $66–$559 $149
2023 $1,134 $233 $82–$673 $160
2024 $1,414 $236 $84–$688 $164
2025 $1,315 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $1,145 83 payments
  2. AbbVie, Inc. $934 63 payments
  3. Neurocrine Biosciences, Inc. $817 41 payments
  4. Vanda Pharmaceuticals Inc. $581 27 payments
  5. Teva Pharmaceuticals USA, Inc. $526 26 payments
  6. ITI, Inc. $522 20 payments
  7. Alkermes, Inc. $460 23 payments
  8. Inari Medical, Inc. $224 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $194 18 payments
  10. E.R. Squibb & Sons, L.L.C. $136 6 payments
  11. Other $390 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,879 339 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. REXULTI $881 65 payments
  2. VRAYLAR $793 53 payments
  3. INGREZZA $705 32 payments
  4. FANAPT $581 27 payments
  5. CAPLYTA $486 18 payments
  6. FLOWTRIEVER CATHETER, S $447 24 payments
  7. LYBALVI $419 21 payments
  8. ARISTADA Cns $272 19 payments
  9. ARISTADA Cns $272 19 payments
  10. ARISTADA Cns $272 19 payments
  11. Other $2,780 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

3,479

Median for Nurse Practitioner: 389

Drug cost

$645,727

Median for Nurse Practitioner: $21,885

Branded share of claims

15.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 16 $128,919
Austedo Deutetrabenazine Brand 20 $120,731
Invega Sustenna Paliperidone Palmitate Brand 29 $93,335
Rexulti Brexpiprazole Brand 37 $75,831
Abilify Maintena Aripiprazole Brand 20 $55,752
Vraylar Cariprazine Hcl Brand 28 $43,897
Caplyta Lumateperone Tosylate Brand 13 $22,705
Lurasidone Hcl Generic 71 $10,448
Aripiprazole Generic 134 $6,160
Paliperidone Er Paliperidone Brand 36 $5,907

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$13,285

Medicare's payments for the services billed

Medicare patients

41

Average age 64

Services billed

178

25 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Depression 68%
Diabetes 46%
Arthritis 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $270
$270 28 —
FANAPT
  • Vanda Pharmaceuticals Inc. $216
$216 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $188
$188 16 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $147
$147 20 —
CAPLYTA
  • ITI, Inc. $140
$140 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record